{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T02:12:14Z","timestamp":1776737534075,"version":"3.51.2"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.msard.2020.102157","type":"journal-article","created":{"date-parts":[[2020,5,15]],"date-time":"2020-05-15T12:33:17Z","timestamp":1589545997000},"page":"102157","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["A case of drug-induced bullous pemphigoid associated with teriflunomide: A patient with relapsing multiple sclerosis"],"prefix":"10.1016","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4270-3217","authenticated-orcid":false,"given":"Doruk","family":"Arslan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmet Burhan","family":"Aksakal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00d6zlem","family":"Erdem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meryem Asl\u0131","family":"Tuncer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.msard.2020.102157_bib0001","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s40265-014-0212-x","article-title":"Teriflunomide and its mechanism of action in multiple sclerosis","volume":"74","author":"Bar-Or","year":"2014","journal-title":"Drugs"},{"issue":"2","key":"10.1016\/j.msard.2020.102157_bib0011","doi-asserted-by":"crossref","first-page":". 223-7","DOI":"10.1111\/j.1365-2125.1982.tb01361.x","article-title":"Comparison of two recently published algorithms for assessing the probability of adverse drug reactions","volume":"13","author":"Busto","year":"1982","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"4","key":"10.1016\/j.msard.2020.102157_bib0019","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1093\/annonc\/mdv623","article-title":"Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper","volume":"27","author":"Champiat","year":"2016","journal-title":"Ann. Oncol."},{"issue":"12","key":"10.1016\/j.msard.2020.102157_bib0006","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1111\/ijd.13742","article-title":"Teriflunomide-induced psoriasiform changes of fingernails: a new example of paradoxical side effect?","volume":"56","author":"Dereure","year":"2017","journal-title":"Int. J. Dermatol."},{"issue":"11","key":"10.1016\/j.msard.2020.102157_bib0005","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1177\/1352458515596601","article-title":"Fatal toxic epidermal necrolysis in a patient on teriflunomide treatment for relapsing multiple sclerosis","volume":"21","author":"Gerschenfeld","year":"2015","journal-title":"Mult. Scler."},{"issue":"1","key":"10.1016\/j.msard.2020.102157_bib0002","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.neuron.2006.09.011","article-title":"The neurobiology of multiple sclerosis: genes, inflammation, and neurodegeneration","volume":"52","author":"Hauser","year":"2006","journal-title":"Neuron"},{"issue":"1-2","key":"10.1016\/j.msard.2020.102157_bib0015","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s12016-007-0030-y","article-title":"The pathophysiology of bullous pemphigoid","volume":"33","author":"Kasperkiewicz","year":"2007","journal-title":"Clin. Rev. Allergy Immunol."},{"issue":"10","key":"10.1016\/j.msard.2020.102157_bib0020","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1634\/theoncologist.2018-0128","article-title":"A Case of Nivolumab-Induced Bullous Pemphigoid: Review of Dermatologic Toxicity Associated with Programmed Cell Death Protein-1\/Programmed Death Ligand-1 Inhibitors and Recommendations for Diagnosis and Management","volume":"23","author":"Lopez","year":"2018","journal-title":"Oncologist"},{"key":"10.1016\/j.msard.2020.102157_bib0007","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.msard.2017.09.029","article-title":"\"Nail loss after teriflunomide treatment: A new potential adverse event\"","volume":"18","author":"Mancinelli","year":"2017","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"2","key":"10.1016\/j.msard.2020.102157_bib0017","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1590\/abd1806-4841.20199007","article-title":"Bullous pemphigoid","volume":"94","author":"Miyamoto","year":"2019","journal-title":"An. Bras. Dermatol."},{"issue":"2","key":"10.1016\/j.msard.2020.102157_bib0012","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin. Pharmacol. Ther."},{"issue":"5","key":"10.1016\/j.msard.2020.102157_bib0018","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1158\/2326-6066.CIR-15-0123","article-title":"Autoimmune Bullous Skin Disorders with Immune Checkpoint Inhibitors Targeting PD-1 and PD-L1","volume":"4","author":"Naidoo","year":"2016","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.msard.2020.102157_bib0008","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.msard.2018.11.020","article-title":"Palmar pustular psoriasis associated with teriflunomide treatment","volume":"27","author":"Negrotto","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"5","key":"10.1016\/j.msard.2020.102157_bib0013","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/j.1365-4362.1991.tb03867.x","article-title":"Pemphigus and bullous pemphigoid due to drugs","volume":"30","author":"Ruocco","year":"1991","journal-title":"Int. J. Dermatol."},{"issue":"5 Pt 2","key":"10.1016\/j.msard.2020.102157_bib0016","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/0190-9622(93)70262-R","article-title":"Antigen identification in drug-induced bullous pemphigoid","volume":"29","author":"Smith","year":"1993","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.msard.2020.102157_bib0004","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1146\/annurev.immunol.23.021704.115707","article-title":"Immunology of multiple sclerosis","volume":"23","author":"Sospedra","year":"2005","journal-title":"Annu. Rev. Immunol."},{"issue":"9","key":"10.1016\/j.msard.2020.102157_bib0010","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1111\/jdv.12366","article-title":"Drug-induced pemphigoid: a review of the literature","volume":"28","author":"Stavropoulos","year":"2014","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/j.msard.2020.102157_bib0003","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1146\/annurev.neuro.30.051606.094313","article-title":"Multiple sclerosis: an immune or neurodegenerative disorder?","volume":"31","author":"Trapp","year":"2008","journal-title":"Annu. Rev. Neurosci."},{"issue":"3","key":"10.1016\/j.msard.2020.102157_bib0009","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.det.2011.03.008","article-title":"Pathogenesis of bullous pemphigoid","volume":"29","author":"Ujiie","year":"2011","journal-title":"Dermatol. Clin."},{"issue":"3","key":"10.1016\/j.msard.2020.102157_bib0014","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S0738-081X(98)00008-X","article-title":"Drug-induced pemphigoid: bullous and cicatricial","volume":"16","author":"Vassileva","year":"1998","journal-title":"Clin. Dermatol."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034820302339?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034820302339?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:49:28Z","timestamp":1761900568000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034820302339"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":20,"alternative-id":["S2211034820302339"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2020.102157","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A case of drug-induced bullous pemphigoid associated with teriflunomide: A patient with relapsing multiple sclerosis","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2020.102157","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102157"}}